NO20060196L - Antranilamidpyridoner som inhiberer VEGFR-2 og VEGFR-3 - Google Patents
Antranilamidpyridoner som inhiberer VEGFR-2 og VEGFR-3Info
- Publication number
- NO20060196L NO20060196L NO20060196A NO20060196A NO20060196L NO 20060196 L NO20060196 L NO 20060196L NO 20060196 A NO20060196 A NO 20060196A NO 20060196 A NO20060196 A NO 20060196A NO 20060196 L NO20060196 L NO 20060196L
- Authority
- NO
- Norway
- Prior art keywords
- vegfr
- pyridones
- inhibit
- anthranilamide
- antianilamide
- Prior art date
Links
- BJHCYTJNPVGSBZ-YXSASFKJSA-N 1-[4-[6-amino-5-[(Z)-methoxyiminomethyl]pyrimidin-4-yl]oxy-2-chlorophenyl]-3-ethylurea Chemical compound CCNC(=O)Nc1ccc(Oc2ncnc(N)c2\C=N/OC)cc1Cl BJHCYTJNPVGSBZ-YXSASFKJSA-N 0.000 title abstract 2
- 108010053099 Vascular Endothelial Growth Factor Receptor-2 Proteins 0.000 title abstract 2
- 108010053100 Vascular Endothelial Growth Factor Receptor-3 Proteins 0.000 title abstract 2
- 102100033177 Vascular endothelial growth factor receptor 2 Human genes 0.000 title abstract 2
- 102100033179 Vascular endothelial growth factor receptor 3 Human genes 0.000 title abstract 2
- NXMIGTZIQNBDKA-UHFFFAOYSA-N 2-aminobenzamide;1h-pyridin-2-one Chemical class O=C1C=CC=CN1.NC(=O)C1=CC=CC=C1N NXMIGTZIQNBDKA-UHFFFAOYSA-N 0.000 title 1
- 230000033115 angiogenesis Effects 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 230000002085 persistent effect Effects 0.000 abstract 1
- UBQKCCHYAOITMY-UHFFFAOYSA-N pyridin-2-ol Chemical class OC1=CC=CC=N1 UBQKCCHYAOITMY-UHFFFAOYSA-N 0.000 abstract 1
- 230000001960 triggered effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/62—Oxygen or sulfur atoms
- C07D213/63—One oxygen atom
- C07D213/64—One oxygen atom attached in position 2 or 6
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Dermatology (AREA)
- Ophthalmology & Optometry (AREA)
- Urology & Nephrology (AREA)
- Oncology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Rheumatology (AREA)
- Hematology (AREA)
- Neurosurgery (AREA)
- Diabetes (AREA)
- Neurology (AREA)
- Vascular Medicine (AREA)
- Transplantation (AREA)
- Pain & Pain Management (AREA)
- Surgery (AREA)
- Biomedical Technology (AREA)
- Gastroenterology & Hepatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pyridine Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE10327719A DE10327719A1 (de) | 2003-06-13 | 2003-06-13 | VEGFR-2 und VEGFR-3 Inhibitorische Anthranylamidpyridone |
| PCT/EP2004/006236 WO2004111005A1 (de) | 2003-06-13 | 2004-06-09 | Vegfr-2 und vegfr-3 inhibitorische anthranylamidpyridone |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NO20060196L true NO20060196L (no) | 2006-01-12 |
Family
ID=33520741
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20060196A NO20060196L (no) | 2003-06-13 | 2006-01-12 | Antranilamidpyridoner som inhiberer VEGFR-2 og VEGFR-3 |
Country Status (18)
| Country | Link |
|---|---|
| EP (1) | EP1633713A1 (uk) |
| JP (1) | JP2006527228A (uk) |
| KR (1) | KR20060021887A (uk) |
| CN (1) | CN1805936A (uk) |
| AU (1) | AU2004247377A1 (uk) |
| BR (1) | BRPI0411360A (uk) |
| CA (1) | CA2526041A1 (uk) |
| CR (1) | CR8127A (uk) |
| DE (1) | DE10327719A1 (uk) |
| EA (1) | EA200501885A1 (uk) |
| EC (1) | ECSP066280A (uk) |
| IL (1) | IL171898A0 (uk) |
| MX (1) | MXPA05013586A (uk) |
| NO (1) | NO20060196L (uk) |
| RS (1) | RS20050831A (uk) |
| UA (1) | UA81323C2 (uk) |
| WO (1) | WO2004111005A1 (uk) |
| ZA (1) | ZA200600291B (uk) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20060071812A (ko) * | 2004-12-22 | 2006-06-27 | 주식회사 엘지생명과학 | 신규한 3-(2-아미노-6-피리디닐)-4-히드록시페닐 아민유도체 |
| US9376393B2 (en) * | 2012-01-05 | 2016-06-28 | Clanotech Ab | Quinoline compounds which are anti-angiogenic integrin alpha5 beta1 inhibitors for use in the treatment of fibrosis or fibrosis-related diseases |
| CN106496107A (zh) * | 2016-08-31 | 2017-03-15 | 浙江永宁药业股份有限公司 | Vegfr‑2抑制剂及其制备方法 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UA71587C2 (uk) * | 1998-11-10 | 2004-12-15 | Шерінг Акцієнгезелльшафт | Аміди антранілової кислоти та їхнє застосування як лікарських засобів |
| GB9824579D0 (en) * | 1998-11-10 | 1999-01-06 | Novartis Ag | Organic compounds |
| DE10023486C1 (de) * | 2000-05-09 | 2002-03-14 | Schering Ag | Ortho substituierte Anthranilsäureamide und deren Verwendung als Arzneimittel |
| MXPA03010099A (es) * | 2001-05-08 | 2004-03-10 | Schering Ag | Amidas de antranilamida-piridina selectivas como inhibidores de vegfr-2 y vegfr-3. |
| GB0126902D0 (en) * | 2001-11-08 | 2002-01-02 | Novartis Ag | Organic compounds |
| DE10228090A1 (de) * | 2002-06-19 | 2004-01-15 | Schering Ag | Ausgewählte Anthranylamidpyridinamide und deren Verwendung als Arzneimittel |
-
2003
- 2003-06-13 DE DE10327719A patent/DE10327719A1/de not_active Ceased
-
2004
- 2004-06-09 AU AU2004247377A patent/AU2004247377A1/en not_active Abandoned
- 2004-06-09 BR BRPI0411360-8A patent/BRPI0411360A/pt not_active IP Right Cessation
- 2004-06-09 KR KR1020057023901A patent/KR20060021887A/ko not_active Withdrawn
- 2004-06-09 CN CNA2004800163643A patent/CN1805936A/zh active Pending
- 2004-06-09 EA EA200501885A patent/EA200501885A1/ru unknown
- 2004-06-09 MX MXPA05013586A patent/MXPA05013586A/es unknown
- 2004-06-09 WO PCT/EP2004/006236 patent/WO2004111005A1/de not_active Ceased
- 2004-06-09 RS YUP-2005/0831A patent/RS20050831A/sr unknown
- 2004-06-09 JP JP2006515873A patent/JP2006527228A/ja active Pending
- 2004-06-09 CA CA002526041A patent/CA2526041A1/en not_active Abandoned
- 2004-06-09 EP EP04739742A patent/EP1633713A1/de not_active Withdrawn
- 2004-09-06 UA UAA200512752A patent/UA81323C2/uk unknown
-
2005
- 2005-11-10 IL IL171898A patent/IL171898A0/en unknown
- 2005-12-09 CR CR8127A patent/CR8127A/es not_active Application Discontinuation
-
2006
- 2006-01-12 EC EC2006006280A patent/ECSP066280A/es unknown
- 2006-01-12 NO NO20060196A patent/NO20060196L/no not_active Application Discontinuation
- 2006-01-12 ZA ZA200600291A patent/ZA200600291B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2004111005A1 (de) | 2004-12-23 |
| MXPA05013586A (es) | 2006-03-09 |
| ZA200600291B (en) | 2007-03-28 |
| UA81323C2 (en) | 2007-12-25 |
| ECSP066280A (es) | 2006-07-28 |
| DE10327719A1 (de) | 2005-01-20 |
| CR8127A (es) | 2006-05-29 |
| IL171898A0 (en) | 2006-04-10 |
| AU2004247377A1 (en) | 2004-12-23 |
| CA2526041A1 (en) | 2004-12-23 |
| CN1805936A (zh) | 2006-07-19 |
| EP1633713A1 (de) | 2006-03-15 |
| KR20060021887A (ko) | 2006-03-08 |
| EA200501885A1 (ru) | 2006-06-30 |
| BRPI0411360A (pt) | 2006-07-25 |
| RS20050831A (sr) | 2008-04-04 |
| JP2006527228A (ja) | 2006-11-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO20072804L (no) | Antranilamidpyridinureaer som VEGF-reseptorkinaseinhibitorer | |
| LT2878297T (lt) | Medikamentai, skirti fibrozinių ligų gydymui arba prevencijai | |
| NO20072802L (no) | Nye antranilamidpyridinureaer som vaskulaerendotelvekstfaktor (VEGF) -reseptorkinaseinhibitorer | |
| TW200738724A (en) | Substituted 4-amino-pyrrolotriazine derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis | |
| HN2005000255A (es) | Derivados de pirrolotriazina utiles para tratar trastornos hiper-proliferativos y enfermedades asociadas con angiogenesis | |
| NO20085100L (no) | Nye forbindelser | |
| NO20065847L (no) | Difenylimidazopyrimidiner og -imidazolaminer som inhibitorer av B-sekretase | |
| NO20070866L (no) | Antivirale forbindelser. | |
| NO20090783L (no) | Pyrimidonforbindelser som inhibitorer av GSK-3 | |
| ATE416177T1 (de) | Hetaryloxy-substituierte phenylaminopyrimidine als rho-kinasehemmer | |
| WO2007127474A3 (en) | Compositions and treatments using pyridazine compounds and cholinesterase inhibitors | |
| ATE528002T1 (de) | Pyridoncarboxamidderivate zur behandlung hyperproliferativer und angiogenese-vermittelter leiden | |
| DE602007005120D1 (de) | 2-pyridonderivate zur behandlung von krankheiten oder leiden, bei denen eine inhibierung der aktivität der neutrophilen elastase von nutzen ist | |
| TN2017000158A1 (en) | Carbazole derivatives | |
| NO20070081L (no) | Sulfamat og sulfamidderivater for behandling av epilepsi og relaterte sykdommer | |
| DK2105164T3 (da) | Nye P2X7R-antagonister og deres anvendelse | |
| DK2243772T3 (da) | Hidtil ukendte P2X7R-antagonister og deres anvendelse | |
| DK1423384T3 (da) | Pyridinderivater som Raf kinaseinhibitorer | |
| TW200611695A (en) | Pyrrolopyridine derivatives | |
| NO20054371L (no) | Somatostatin-dopamin kimaere analoger | |
| DK2422786T3 (da) | Nye lægemiddelkombinationer til behandling af luftvejssygdomme | |
| NO20054494L (no) | Peptidvektorer | |
| DK1610787T3 (da) | Synergistisk kombination der omfatter roflumilast og et antikolinergt middel der er valgt blandt tiotropiumsalte til behandling af respiratoriske sygdomme | |
| SI1940409T1 (sl) | Nove zdravilske kombinacije za zdravljenje bolezni dihalnih poti | |
| TW200738699A (en) | 4-Substituted pyrazoline compounds, their preparation and use as medicaments |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC2A | Withdrawal, rejection or dismissal of laid open patent application |